Cargando…
Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
OBJECTIVE: Prostate cancer (PCa) is the second most common male malignancy globally. Prostate-specific antigen (PSA) is an important biomarker for PCa diagnosis. However, it is not accurate in the diagnostic gray zone of 4–10 ng/ml of PSA. In the current study, the performance of serum metabolomics...
Autores principales: | Xu, Bei, Chen, Yan, Chen, Xi, Gan, Lingling, Zhang, Yamei, Feng, Jiafu, Yu, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554118/ https://www.ncbi.nlm.nih.gov/pubmed/34722271 http://dx.doi.org/10.3389/fonc.2021.730638 |
Ejemplares similares
-
A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone
por: Kang, Ho Won, et al.
Publicado: (2020) -
Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia
por: Pérez-Rambla, Clara, et al.
Publicado: (2017) -
Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia
por: Hsiao, Chun-Jen, et al.
Publicado: (2016) -
Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia
por: Fu, Shuang, et al.
Publicado: (2018) -
Benign Prostatic Hyperplasia
Publicado: (2015)